中科生物(01237.HK)附属拟出资1530万元成立合资公司
格隆汇5月25日丨中科生物(01237.HK)发布公告,2021年5月25日,公司的非直接全资附属公司木村及漳州森蕴订立协议以成立合资公司,并在中国经营建筑装饰材料,林业产品及木材的采购及销售。根据协议,合资公司的注册资本将为人民币3000万元,木村将出资人民币1530万元,漳州森蕴将出资人民币1470万元,分别占合资公司的总注册资本的51%及49%。
董事相信成立合资公司将有助集团利用漳州成熟的木产品产业链及邻近港口的地理优势,丰富集团的产品组合以满足集团客户不断增长的需求,并维持价格优势,保持集团的竞争力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.